Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Her2 Positive Metastatic Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT01697293
What this trial is testing

PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer

Who this might be right for
Breast AdenocarcinomaEstrogen Receptor PositiveHER2/Neu Negative+6 more
Prescient Therapeutics, Ltd. 34
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07545044
What this trial is testing

JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer

Who this might be right for
HER2-positive Recurrent or Metastatic Breast Cancer
Shanghai JMT-Bio Inc. 60
Early research (Phase 1)Study completedNCT04509596
What this trial is testing

DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer

Who this might be right for
Breast Cancer Metastatic
Dizal Pharmaceuticals 23
Large-scale testing (Phase 3)WithdrawnNCT06585969
What this trial is testing

A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerER-positive Breast CancerLuminal B+2 more
Danish Breast Cancer Cooperative Group
Testing effectiveness (Phase 2)Looking for participantsNCT06974604
What this trial is testing

Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM

Who this might be right for
Breast NeoplasmsLung Neoplasms
Brown University 60
Large-scale testing (Phase 3)Ended earlyNCT00968968
What this trial is testing

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Who this might be right for
Cancer
Novartis Pharmaceuticals 37
Testing effectiveness (Phase 2)Ended earlyNCT03519178
What this trial is testing

PF-06873600 in People With Cancer

Who this might be right for
HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer
Pfizer 155
Testing effectiveness (Phase 2)Looking for participantsNCT05982678
What this trial is testing

Basket Study for Oligo-metastatic Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
The Netherlands Cancer Institute 72
Not applicableStudy completedNCT00896376
What this trial is testing

Trastuzumab in Treating Women With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Centre Antoine Lacassagne 49
Large-scale testing (Phase 3)Active Not RecruitingNCT06016738
What this trial is testing

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

Who this might be right for
Breast CancerAdvanced Breast CancerMetastatic Breast Cancer+2 more
Olema Pharmaceuticals, Inc. 510
Testing effectiveness (Phase 2)Study completedNCT00788333
What this trial is testing

Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast Cancer

Who this might be right for
Breast Cancer
Bristol-Myers Squibb 40
Early research (Phase 1)Study completedNCT03364348
What this trial is testing

4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer

Who this might be right for
HER2 Positive Breast CarcinomaRecurrent Breast CarcinomaStage III Breast Cancer+4 more
George W. Sledge Jr. 18
Not applicableStudy completedNCT01777958
What this trial is testing

HELENA Study: An Observational Study of Perjeta (Pertuzumab) in First-Line Treatment in Patients With Her2-Positive Advanced Breast Cancer After Adjuvant Herceptin Therapy

Who this might be right for
Breast Cancer
Hoffmann-La Roche 135
Large-scale testing (Phase 3)Not Yet RecruitingNCT07578116
What this trial is testing

Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Metastatic HER2-Positive Breast CarcinomaOligometastatic Breast Carcinoma
SWOG Cancer Research Network 562
Testing effectiveness (Phase 2)Study completedNCT00444535
What this trial is testing

Lapatinib and Bevacizumab for Metastatic Breast Cancer

Who this might be right for
Neoplasms, Breast
Novartis Pharmaceuticals 52
Testing effectiveness (Phase 2)Study completedNCT03878823
What this trial is testing

Safety and Pharmacokinetics of ODM-209

Who this might be right for
Prostate Cancer MetastaticAdvanced Breast CancerCastration-resistant Prostate Cancer+1 more
Orion Corporation, Orion Pharma 38
Not applicableStudy completedNCT05584644
What this trial is testing

Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer

Who this might be right for
Breast CancerBreast CarcinomaBreast Neoplasms+2 more
Pfizer 150
Early research (Phase 1)Study completedNCT03953833
What this trial is testing

B003 in Patients With HER2-positive Recurrent or Metastatic Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Shanghai Pharmaceuticals Holding Co., Ltd 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT05323955
What this trial is testing

Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib

Who this might be right for
Brain MetastasesHuman Epidermal Growth Factor 2 Positive Carcinoma of BreastAdvanced Breast Cancer
Carey Anders, M.D. 48
Large-scale testing (Phase 3)Study completedNCT00390455
What this trial is testing

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

Who this might be right for
Estrogen Receptor PositiveHER2 Positive Breast CarcinomaHER2/Neu Negative+5 more
National Cancer Institute (NCI) 295
Next Page